NCT00192101View on ClinicalTrials.gov

Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2004

Study Completion Date

July 31, 2005

Conditions
Metastatic Breast Cancer
Interventions
DRUG

gemcitabine

DRUG

cisplatin

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Jeddah

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00192101 - Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes | Biotech Hunter | Biotech Hunter